BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1161 related articles for article (PubMed ID: 20400460)

  • 21. Targeting RACK1 to alleviate TDP-43 and FUS proteinopathy-mediated suppression of protein translation and neurodegeneration.
    Zhao B; Cowan CM; Coutts JA; Christy DD; Saraph A; Hsueh SCC; Plotkin SS; Mackenzie IR; Kaplan JM; Cashman NR
    Acta Neuropathol Commun; 2023 Dec; 11(1):200. PubMed ID: 38111057
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Functions of FUS/TLS from DNA repair to stress response: implications for ALS.
    Sama RR; Ward CL; Bosco DA
    ASN Neuro; 2014 Jun; 6(4):. PubMed ID: 25289647
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TDP-43 and FUS/TLS: sending a complex message about messenger RNA in amyotrophic lateral sclerosis?
    Strong MJ; Volkening K
    FEBS J; 2011 Oct; 278(19):3569-77. PubMed ID: 21810174
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FUS-related proteinopathies: lessons from animal models.
    Lanson NA; Pandey UB
    Brain Res; 2012 Jun; 1462():44-60. PubMed ID: 22342159
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Requirements for stress granule recruitment of fused in sarcoma (FUS) and TAR DNA-binding protein of 43 kDa (TDP-43).
    Bentmann E; Neumann M; Tahirovic S; Rodde R; Dormann D; Haass C
    J Biol Chem; 2012 Jun; 287(27):23079-94. PubMed ID: 22563080
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia.
    Mackenzie IR; Rademakers R; Neumann M
    Lancet Neurol; 2010 Oct; 9(10):995-1007. PubMed ID: 20864052
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Trends in Understanding the Pathological Roles of TDP-43 and FUS Proteins.
    Buratti E
    Adv Exp Med Biol; 2021; 1281():243-267. PubMed ID: 33433879
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mechanisms Associated with TDP-43 Neurotoxicity in ALS/FTLD.
    Shenouda M; Zhang AB; Weichert A; Robertson J
    Adv Neurobiol; 2018; 20():239-263. PubMed ID: 29916022
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rethinking ALS: the FUS about TDP-43.
    Lagier-Tourenne C; Cleveland DW
    Cell; 2009 Mar; 136(6):1001-4. PubMed ID: 19303844
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Understanding the role of TDP-43 and FUS/TLS in ALS and beyond.
    Da Cruz S; Cleveland DW
    Curr Opin Neurobiol; 2011 Dec; 21(6):904-19. PubMed ID: 21813273
    [TBL] [Abstract][Full Text] [Related]  

  • 31. RNA Granules and Diseases: A Case Study of Stress Granules in ALS and FTLD.
    Fan AC; Leung AK
    Adv Exp Med Biol; 2016; 907():263-96. PubMed ID: 27256390
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FET proteins in frontotemporal dementia and amyotrophic lateral sclerosis.
    Mackenzie IR; Neumann M
    Brain Res; 2012 Jun; 1462():40-3. PubMed ID: 22261247
    [TBL] [Abstract][Full Text] [Related]  

  • 33. RNA-binding proteins with prion-like domains in ALS and FTLD-U.
    Gitler AD; Shorter J
    Prion; 2011; 5(3):179-87. PubMed ID: 21847013
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transportin 1 accumulates specifically with FET proteins but no other transportin cargos in FTLD-FUS and is absent in FUS inclusions in ALS with FUS mutations.
    Neumann M; Valori CF; Ansorge O; Kretzschmar HA; Munoz DG; Kusaka H; Yokota O; Ishihara K; Ang LC; Bilbao JM; Mackenzie IR
    Acta Neuropathol; 2012 Nov; 124(5):705-16. PubMed ID: 22842875
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nuclear transport impairment of amyotrophic lateral sclerosis-linked mutations in FUS/TLS.
    Ito D; Seki M; Tsunoda Y; Uchiyama H; Suzuki N
    Ann Neurol; 2011 Jan; 69(1):152-62. PubMed ID: 21280085
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fused in sarcoma/translocated in liposarcoma: a multifunctional DNA/RNA binding protein.
    Yang S; Warraich ST; Nicholson GA; Blair IP
    Int J Biochem Cell Biol; 2010 Sep; 42(9):1408-11. PubMed ID: 20541619
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Atypical FTLD-FUS associated with ALS-TDP: a case report.
    Kobayashi Z; Arai T; Yokota O; Tsuchiya K; Hosokawa M; Oshima K; Niizato K; Akiyama H; Mizusawa H
    Neuropathology; 2013 Feb; 33(1):83-6. PubMed ID: 22640227
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aberrant interaction between FUS and SFPQ in neurons in a wide range of FTLD spectrum diseases.
    Ishigaki S; Riku Y; Fujioka Y; Endo K; Iwade N; Kawai K; Ishibashi M; Yokoi S; Katsuno M; Watanabe H; Mori K; Akagi A; Yokota O; Terada S; Kawakami I; Suzuki N; Warita H; Aoki M; Yoshida M; Sobue G
    Brain; 2020 Aug; 143(8):2398-2405. PubMed ID: 32770214
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fused in sarcoma (FUS): an oncogene goes awry in neurodegeneration.
    Dormann D; Haass C
    Mol Cell Neurosci; 2013 Sep; 56():475-86. PubMed ID: 23557964
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of TDP-43 in the pathogenesis of ALS and FTLD.
    Baralle M; Buratti E; Baralle FE
    Biochem Soc Trans; 2013 Dec; 41(6):1536-40. PubMed ID: 24256250
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 59.